Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Conditions: Cutaneous Squamous Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Australia Health | Cancer & Oncology | Carcinoma | Melanoma | Neoadjuvant Therapy | Research | Skin Cancer | Squamous Cell Carcinoma